Pharmacosmos sees big potential in million-dollar acquisition
Family-owned Pharmacosmos wants to grow, which is why the company has paid up to USD 225m for US-based Abfero Pharmaceuticals last week, also acquiring its lead candidate SP-420 that Pharmacosmos says has a promising future ahead.
by ANDREAS LØNSTRUP, translated by daniel pedersen
Pharmacosmos took out the the big checkbook last week, when the family-owned company, which is based in Denmark, acquired the privately owned Boston-based business Abfero Pharmaceuticals.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Pharmacosmos settles legal dispute with Vifor
For subscribers
.jpg&w=384&q=75)
